SCHEMBL10099798

SCHEMBL10099798

C=CC(=O)OCCC(C)(C)SSC(C)(C)CCOC(=O)C=C

nearest known ligand 0.50

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TSHR P16473 7/20 0.50
ALDH1A1 P00352 4/20 0.50
TP53 P04637 3/20 0.50
HIF1A Q16665 3/20 0.50
CYP3A4 P08684 2/20 0.50
HPGD P15428 1/20 0.50
HSD17B10 Q99714 1/20 0.50
THRB P10828 2/20 0.46
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18878219 0.92 TSHR (0.43) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL17717899 0.85 TSHR (0.46) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL1015244 0.82 TSHR (0.56) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL8966168 0.82 TSHR (0.56) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL2741578 0.82 TSHR (0.56) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL18051631 0.80 TSHR (0.54) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL4653958 0.80 TSHR (0.54) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL28272864 0.80 TSHR (0.54) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL23214366 0.78 TSHR (0.52) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL1462384 0.78 TSHR (0.52) TSHRALDH1A1TP53HIF1ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3643318-A1 A BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES The Johns Hopkins University (US) 2020-04-29 EP disclosed
EP-3003343-B1 A BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES UNIV JOHNS HOPKINS (US) 2019-10-23 EP disclosed
US-20180134753-A1 BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES THE JOHNS HOPKINS UNIVERSITY 2018-05-17 US disclosed
US-20180028455-A1 PEPTIDE/PARTICLE DELIVERY SYSTEMS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-02-01 US disclosed
US-9802984-B2 Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases THE JOHNS HOPKINS UNIVERSITY (US) 2017-10-31 US disclosed
US-9802984-B2 Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases THE JOHNS HOPKINS UNIVERSITY (US) 2017-10-31 US disclosed
US-9717694-B2 Peptide/particle delivery systems THE JOHNS HOPKINS UNIVERSITY (US) 2017-08-01 US disclosed
US-9717694-B2 Peptide/particle delivery systems THE JOHNS HOPKINS UNIVERSITY (US) 2017-08-01 US disclosed
US-20160374949-A9 PEPTIDE/PARTICLE DELIVERY SYSTEMS THE JOHNS HOPKINS UNIVERSITY (US) 2016-12-29 US disclosed
US-20150272900-A1 Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics THE JOHNS HOPKINS UNIVERSITY 2015-10-01 US disclosed
US-20150272900-A1 Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics THE JOHNS HOPKINS UNIVERSITY 2015-10-01 US disclosed
US-20140294909-A1 NANOCOMPOSITES OF GOLD AND POLYMERS THE JOHNS HOPKINS UNIVERSITY (US) 2014-10-02 US disclosed
US-20140294909-A1 NANOCOMPOSITES OF GOLD AND POLYMERS THE JOHNS HOPKINS UNIVERSITY (US) 2014-10-02 US disclosed
WO-2014066898-A9 A LAYER-BY-LAYER APPROACH TO CO-DELIVER DNA AND SIRNA VIA AUNPS: A POTENTIAL PLATFORM FOR MODIFYING RELEASE KINETICS THE JOHNS HOPKINS UNIVERSITY (US) 2014-06-05 WO disclosed
WO-2014066898-A1 A LAYER-BY-LAYER APPROACH TO CO-DELIVER DNA AND SIRNA VIA AUNPS: A POTENTIAL PLATFORM FOR MODIFYING RELEASE KINETICS THE JOHNS HOPKINS UNIVERSITY (US) 2014-05-01 WO disclosed
WO-2013056113-A1 NANOCOMPOSITES OF GOLD AND POLYMERS THE JOHNS HOPKINS UNIVERSITY (US) 2013-04-18 WO disclosed
US-20120114759-A1 PEPTIDE/PARTICLE DELIVERY SYSTEMS THE JOHNS HOPKINS UNIVERSITY (US) 2012-05-10 US disclosed
US-20120114759-A1 PEPTIDE/PARTICLE DELIVERY SYSTEMS THE JOHNS HOPKINS UNIVERSITY (US) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160374949-A9 PEPTIDE/PARTICLE DELIVERY SYSTEMS VEGFA, IAPP, FLT1 TSHR 2490/4885ALDH1A1 4007/4885TP53 324/4885
US-20150272900-A1 Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics DNMT3L, DBNL, HNRNPL TSHR 2581/4885ALDH1A1 2087/4885TP53 892/4885
US-20120114759-A1 PEPTIDE/PARTICLE DELIVERY SYSTEMS VEGFA, IAPP, FLT1 TSHR 2490/4885ALDH1A1 4007/4885TP53 324/4885
US-20180134753-A1 BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES VEGFA, LRRFIP1, FLT1 TSHR 2635/4885ALDH1A1 3587/4885TP53 1625/4885
US-20180028455-A1 PEPTIDE/PARTICLE DELIVERY SYSTEMS VEGFA, IAPP, FLT1 TSHR 2490/4885ALDH1A1 4007/4885TP53 324/4885
US-20140294909-A1 NANOCOMPOSITES OF GOLD AND POLYMERS HNRNPL, HNRNPLL, ACSL3 TSHR 1764/4885ALDH1A1 883/4885TP53 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.